Uroplasty Reports Record Revenue in Fiscal Third Quarter

~ Global Urgent PC Sales Up 14.5%

~~ Proposed Merger with Vision-Sciences to Expand Innovation in Product Portfolio

Jan 22, 2015, 16:01 ET from Uroplasty, Inc.

MINNEAPOLIS, Jan. 22, 2015 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fiscal 2015 third quarter ended December 31, 2014. 

Global revenue for the Company's Urgent® PC Neuromodulation System grew 14.5% to $4.4 million, a new quarterly revenue record, as compared to $3.9 million in the third quarter of the prior year.  Global Macroplastique sales were $2.0 million during the third quarter as compared to $2.3 million in the third quarter of fiscal 2014.  Total revenue for the third quarter of fiscal 2015 was $6.7 million, a 4.2% increase from the same quarter in the prior year. The impact of changes in foreign currency exchange rates negatively impacted revenue by approximately $0.1 million. Adjusting for the negative impact of foreign currency exchange rates, year-over-year total revenue growth would have been 5.7% in the fiscal third quarter, and Urgent PC revenue growth would have been 15.5%.

On December 22, 2014, the Company and Vision-Sciences, Inc. announced that they had entered into an agreement and plan of merger under which the two companies will combine in an all-stock transaction to create a new medical device company to be named Cogentix Medical, Inc. The proposed merger is expected to be completed in the first half of calendar 2015, subject to shareholder and other customary approvals.  The combined company is expected to generate revenue growth between 10% and 14% in its first fiscal year beginning on April 1, 2015.  Once the existing Uroplasty sales team is fully trained on Vision-Sciences' EndoSheath technology platform, the combined company is expected to achieve sustainable annual revenue growth of 15% beginning with its second fiscal year. 

"Third quarter and year-to-date revenue growth for Urgent PC illustrates the ability of our sales organization to penetrate the urology market with innovative technologies that address key needs of our physician customers," said Rob Kill, President and Chief Executive Officer of Uroplasty. "Our team's execution during our fiscal third quarter gives us a high level of confidence about the potential to accelerate EndoSheath sales in the in-office urology market once we complete the proposed merger with Vision-Sciences.  With more than five million units sold and zero reported cases of cross contamination, we believe that EndoSheath should be the standard of care for endoscopic applications, and our team fully intends to turn this efficacy leadership into market leadership," added Mr. Kill.   

In the fiscal third quarter, the Company achieved a gross margin of 88.3%, 50 basis points higher than the 87.8% gross margin in the same quarter one year ago.  Operating expenses for the period totaled $8.0 million compared to $6.3 million in the same quarter last year and includes approximately $820,000 of transaction expenses incurred in the third quarter associated with the proposed Vision-Sciences merger.

The operating loss of $2.1 million in the fiscal third quarter compares with a $0.7 million operating loss in the same quarter last year.  Excluding non-cash charges for share-based compensation and depreciation and amortization expense, the non-GAAP operating loss was $1.5 million ($0.7 million excluding merger related costs) in the third quarter of fiscal 2015, compared with a $0.3 million non-GAAP operating loss in the year ago period.

The loss per diluted share of $0.10 in the fiscal third quarter compares to a loss per diluted share of $0.03 in the same quarter last year.  Excluding merger related costs, the non-GAAP loss per diluted share in the third quarter of fiscal 2015 was $0.06.

For the nine-month period ended December 31, 2014, global revenue from Urgent PC increased 17.1% to $12.7 million.  Total revenue grew 7.1% to $19.5 million.  At December 31, 2014, cash, cash equivalents and cash investments totaled $8.7 million.  During the third quarter, the Company used $0.7 million in cash for operations.

For the fourth quarter of fiscal 2015, the Company currently expects Urgent PC sales to grow approximately 15% over the same quarter of the prior fiscal year and currently expects global Macroplastique sales to be approximately $2.0 million, which is consistent with the revenue generated from this product line over the prior four quarters.  Total fiscal year 2015 revenue is now expected to be in a range from $26.5 million to $26.8 million.  

Conference Call
Uroplasty will host a conference call and webcast today at 4:30 p.m. Eastern Time (3:30 p.m. Central Time) to discuss these results. Rob Kill, President and Chief Executive Officer, and Brett Reynolds, Chief Financial Officer, will host the call. Individuals wishing to participate in the conference call should dial 888-523-1225. No passcode is necessary.  To access a live webcast of the call, go to Uroplasty's website at www.uroplasty.com and click on the Investor Relations section.

An audio replay will be available for 30 days following the call at 888-203-1112 with the passcode 2270603.  An archived webcast will also be available at investor.uroplasty.com.

About Uroplasty
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Uroplasty's focus is the continued commercialization of its Urgent® PC Neuromodulation System, which Uroplasty believes is the only commercially available, FDA-cleared device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB).  OAB is a chronic condition that affects approximately 42 million U.S. adults.  The symptoms include urinary urgency, frequency and urge incontinence.  Uroplasty also offers Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency.  For more information on Uroplasty and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Important Additional Information and Where to Find It

In connection with the proposed merger, Vision-Sciences plans to file with the SEC a registration statement on Form S-4 that will include a joint proxy statement of Uroplasty and Vision-Sciences that also constitutes a prospectus of Vision-Sciences.  Uroplasty and Vision-Sciences will make the joint proxy statement/prospectus available to their respective shareholders. Investors are urged to read the joint proxy statement/prospectus when it becomes available, because it will contain important information. The registration statement, definitive joint proxy statement/prospectus and other documents filed by Uroplasty and Vision-Sciences with the SEC will be available free of charge at the SEC's website (www.sec.gov) and from Uroplasty and Vision-Sciences. Requests for copies of the joint proxy statement/prospectus and other documents filed by Uroplasty with the SEC may be made by contacting Brett Reynolds, Senior Vice President, Chief Financial Officer by phone at (952) 426-6152 or by email at brett.reynolds@uroplasty.com, and request for copies of the joint proxy statement/prospectus and other documents filed by Vision-Sciences may be made by contacting Gary Siegel, Vice President, Finance by phone at (845) 848-1085 or by email at gary.siegel@visionsciences.com.

Participants in the Solicitation

Uroplasty, Vision-Sciences, their respective directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from Uroplasty's and Vision-Sciences' respective shareholders in connection with the proposed transaction.  Information about the directors and executive officers of Uroplasty and their ownership of Uroplasty stock is set forth in Uroplasty's annual report on Form 10-K for the fiscal year ended March 31, 2014,  and its proxy statement for its 2014 annual meeting of shareholders, which was filed with the SEC on July 22, 2014. Information regarding Vision-Sciences' directors and executive officers is contained in Vision-Sciences' annual report on Form 10-K for the fiscal year ended March 31, 2014 and its proxy statement for its 2014 annual meeting of shareholders, which was filed with the SEC on June 17, 2014. These documents can be obtained free of charge from the sources indicated above. Certain directors, executive officers and employees of Uroplasty and Vision-Sciences may have direct or indirect interest in the transaction due to securities holdings, vesting of equity awards and rights to severance payments. Additional information regarding the participants in the solicitation of Uroplasty and Vision-Sciences shareholders will be included in the joint proxy statement/prospectus filed with the SEC.

Cautionary Statements Related to Forward-Looking Statements

This press release includes forward-looking statements.  These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning.  Forward-looking statements in this press release include, but are not limited to, statements about the benefits of the transaction; expected revenue growth rates; the expected timing of the completion of the transaction; and the combined company's plans, objectives, expectations and intentions with respect to future operations, products and services.  Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.  Applicable risks and uncertainties include, among others, uncertainties as to the timing of the transaction; uncertainties as to whether Uroplasty shareholders and Vision-Sciences shareholders will approve the transaction; the risk that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived; the risk that shareholder litigation in connection with the transaction may result in significant costs of defense, indemnification and liability; other business effects, including the effects of industry, economic or political conditions outside of either company's control; the failure to realize synergies and cost-savings from the transaction or delay in realization thereof; the businesses of Uroplasty and Vision-Sciences may not be combined successfully, or such combination may take longer, be more difficult, time-consuming or costly to accomplish than expected; operating costs and business disruption following completion of the transaction, including adverse effects on employee retention and on each company's respective business relationships with third parties; transaction costs; actual or contingent liabilities; the adequacy of the combined company's capital resources; and the risks identified under the heading "Risk Factors" in Uroplasty's Annual Report on Form 10-K, for the fiscal year ended March 31, 2014, filed with the Securities and Exchange Commission ("SEC") on June 9, 2014, and Vision-Sciences' Annual Report on Form 10-K for the fiscal year ended March 31, 2014, filed with the SEC on May 30, 2014, as well as both companies' subsequent Quarterly Reports on Form 10-Q and other information filed by each company with the SEC.  Uroplasty and Vision-Sciences caution investors not to place considerable reliance on the forward-looking statements contained in this press release.  You are encouraged to read Uroplasty's and Vision-Sciences' filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and Uroplasty and Vision-Sciences undertake no obligation to update or revise any of these statements.  Uroplasty's and Vision-Sciences' businesses are subject to substantial risks and uncertainties, including those referenced above.  Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

For Further Information:

Uroplasty, Inc.

Brett Reynolds, SVP and CFO

952-426-6152


EVC Group

Doug Sherk/Brian Moore (Investors)

415-652-9100/310-579-6199

Janine McCargo (Media)

646-688-0425

           

UROPLASTY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)



Three Months Ended

December 31,


Nine Months Ended

December 31,


2014


2013


2014


2013

















Net sales

$6,666,905


$6,398,675


$19,506,164


$18,216,391

Cost of goods sold

778,406


778,267


2,322,942


2,268,156









Gross profit

5,888,499


5,620,408


17,183,222


15,948,235









Operating expenses








       General and administrative

2,283,333


1,194,882


5,148,998


5,166,255

       Research and development

665,539


526,224


2,226,018


1,434,647

       Selling and marketing

5,015,916


4,546,100


15,107,241


13,496,593

       Amortization

7,584


7,873


24,136


22,347


7,972,372


6,275,079


22,506,393


20,119,842









Operating loss

(2,083,873)


(654,671)


(5,323,171)


(4,171,607)









Other income (expense)








       Interest income

1,761


3,836


6,606


18,576

       Interest expense

(250)


-


(250)


-

       Foreign currency exchange gain (loss)

(2,038)


(506)


(3,317)


(4,540)


(527)


3,330


3,039


14,036









Loss before income taxes

(2,084,400)


(651,341)


(5,320,132)


(4,157,571)









Income tax expense

20,938


19,491


55,785


50,033









Net loss

$(2,105,338)


$(670,832)


$(5,375,917)


(4,207,604)









Basic and diluted net loss per common share

$(0.10)


$(0.03)


$(0.25)


$(0.20)









Weighted average common shares outstanding:








       Basic and diluted

21,663,924


21,258,736


21,683,892


21,035,874









 


 

UROPLASTY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)



December 31, 2014


 March 31, 2014





Assets




       Current assets:




           Cash and cash equivalents

$8,703,789


$8,681,609

           Short-term investments

-


3,451,086

           Accounts receivable, net

2,567,403


2,875,275

           Inventories

437,471


517,217

           Other

449,046


507,299

       Total current assets

12,157,709


16,032,486





       Property, plant, and equipment, net

946,726


997,609

       Intangible assets, net

95,845


119,980

       Prepaid pension assets

-


855

       Deferred tax assets

127,625


150,116

       Total assets

$13,327,905


$17,301,046





Liabilities and Shareholders' Equity




       Current liabilities:




           Accounts payable

$1,193,692


$904,879

           Current portion – deferred rent

-


2,917

           Current portion – capital lease obligation

4,434


-

           Income tax payable

23,729


21,922

           Accrued liabilities:




               Compensation

2,199,586


1,999,966

               Other

394,732


479,373





       Total current liabilities

3,816,173


3,409,057





       Deferred rent – less current portion

26,644


171

       Capital lease obligation – less current portion

18,411


-

       Long-term incentive plan

131,907


-

       Accrued pension liability

543,934


678,118





       Total liabilities

4,537,069


4,087,346





       Total shareholders' equity

8,790,836


13,213,700





       Total liabilities and shareholders' equity

$13,327,905


$17,301,046

 

 


 

UROPLASTY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)


Nine Months Ended


December 31,


2014


2013

Cash flows from operating activities:




Net loss

$(5,375,917)


$(4,207,604)

Adjustments to reconcile net loss to net cash used in operating activities:




Depreciation and amortization

207,011


267,369

Loss (gain) on disposal of equipment

161


(5,000)

Amortization of premium on marketable securities

311


7,562

Share-based compensation expense

1,077,928


1,210,201

Long-term incentive plan

131,907


-

Deferred income tax expense

5,129


3,245

Deferred rent

23,556


(27,790)

Changes in operating assets and liabilities:




Accounts receivable, net

220,002


79,428

Inventories

73,626


255,207

Other current assets

48,142


16,868

Accounts payable

295,113


21,724

Accrued compensation

212,259


274,139

Accrued liabilities

(59,459)


(120,881)

Accrued pension liability

(56,226)


(39,011)

Net cash used in operating activities

(3,196,457)


(2,264,543)





Cash flows from investing activities:




Proceeds from maturity of available-for-sale instruments

3,450,000


2,750,000

Proceeds from held-to-maturity instruments

-


4,180,000

Purchases of property, plant and equipment

(206,498)


(221,769)

Proceeds from sale of property, plant and equipment

3,104


6,773

Payments for intangible assets

-


(41,300)

Net cash provided by investing activities

3,246,606


6,673,704





Cash flows from financing activities:




Proceeds from exercise of  stock options

67,850


172,485

Net cash provided by financing activities

67,850


172,485





Effect of exchange rates on cash and cash equivalents

(95,819)


48,741





Net increase in cash and cash equivalents

22,180


4,630,387





Cash and cash equivalents at beginning of period

8,681,609


3,533,864





Cash and cash equivalents at end of period

$8,703,789


$8,164,251





Supplemental disclosure of cash flow information:




Cash paid during the period for income tax

$56,144


$34,640





 


Non-GAAP Financial Measures:  The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. ("GAAP") to non-GAAP financial measures that exclude non-cash charges for share-based compensation, long-term incentive plan, depreciation and amortization from gross profit, operating expenses and operating loss.  The non-GAAP financial measures used by management and disclosed by us are not a substitute for, nor superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP.  We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies.  Therefore, our non-GAAP financial measures may not be comparable to those used by other companies.  We have described the reconciliations of each of our non-GAAP financial measures described above to the most directly comparable GAAP financial measures.

We use these non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes because we believe such measures are one important indicator of the strength and the operating performance of our business.  Analysts and investors frequently ask us for this information.  We believe that they use these measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

Our non-GAAP operating loss during the three months ended December 31, 2014 and 2013 was approximately $1,469,000 and $277,000, respectively.  The increase in non-GAAP operating loss for the three months ended December 31, 2014 over the corresponding period a year ago is attributed to the increase in operating spending and business development expenses, partially offset by the increase in net sales and gross profit percent. Expenses related to business development activity in the quarter were $820,000. Our non-GAAP operating loss during the nine months ended December 31, 2014 and 2013 was $3,906,000 and $2,695,000, respectively.  The increase in the non-GAAP operating loss for the nine months ended December 31, 2014 is attributed to an increase in operating and business development expenses, partially offset by the increase in net sales and gross profit percent.



Expense Adjustments


(dollar amounts in thousands)

GAAP

Share-based 
Compensation

Long-term
Incentive
Plan

Depreciation

Amortization

Non-GAAP

Three Months Ended December 31, 2014






Gross Profit

$5,888

$11

$-

$4

$-

$5,903

% of sales

88.3%





88.6%

Operating Expenses







    General & administrative

2,282

(313)

(132)

(36)

-

1,801

    Research and development

666

(11)

-

-

-

655

    Selling and marketing

5,016

(81)

-

(19)

-

4,916

    Amortization

8

-

-

-

(8)

-


7,972

(405)

(132)

(55)

(8)

7,372

Operating Loss

$(2,084)

$416

$132

$59

$8

$(1,469)








Three Months Ended December 31, 2013






Gross Profit

$5,620

$6

$-

$8

$-

$5,634

% of sales

87.8%





88.1%

Operating Expenses







    General & administrative

1,195

(197)

-

(50)

-

948

    Research and development

526

(11)

-

(1)

-

514

    Selling and marketing

4,546

(75)

-

(22)

-

4,449

    Amortization

8

-

-

-

(8)

-


6,275

(283)

-

(73)

(8)

5,911

Operating Loss

$(655)

$289

$-

$81

$8

$(277)







Expense Adjustments


(dollar amounts in thousands)

GAAP

Share-based 
Expense

Long-term
Incentive
Plan

Depreciation

Amortization

Non-GAAP

Nine Months Ended December 31, 2014






Gross Profit

$17,183

$36

$-

$13

$-

$17,232

% of sales

88.1%





88.3%

Operating Expenses







    General & administrative

5,149

(755)

(132)

(111)

-

4,151

    Research and development

2,226

(41)

-

(2)

-

2,183

    Selling and marketing

15,107

(246)

-

(57)

-

14,804

    Amortization

24

-

-

-

(24)

-


22,506

(1,042)

(132)

(170)

(24)

21,138

Operating Loss

$(5,323)

$1,078

$132

$183

$24

$(3,906)








Nine Months Ended December 31, 2013






Gross Profit

$15,948

$20

$-

$26

$-

$15,994

% of sales

87.5%





87.8%

Operating Expenses







    General & administrative

5,166

(952)

-

(153)

-

4,061

    Research and development

1,435

(36)

-

(3)

-

1,396

    Selling and marketing

13,497

(202)

-

(63)

-

13,232

    Amortization

22

-

-

-

(22)

-


20,120

(1,190)

-

(219)

(22)

18,689

Operating Loss

$(4,172)

$1,210

$-

$245

$22

$(2,695)

 

SOURCE Uroplasty, Inc.



RELATED LINKS

http://www.uroplasty.com